Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02099058
Title A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie

Advanced Solid Tumor


Carboplatin + Telisotuzumab vedotin

Erlotinib + Telisotuzumab vedotin

Telisotuzumab vedotin

Bevacizumab + Telisotuzumab vedotin

Cetuximab + Telisotuzumab vedotin

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | BEL

No variant requirements are available.